Efficacy of baloxavir marboxil as a prophylactic against influenza among in-patients and analysis of influenza virus mutations in their isolates at a Japanese hospital during the 2023-2024 flu season.

IF 1.2 Q4 PHARMACOLOGY & PHARMACY
Akihide Fujii, Tomohiro Oishi, Eisei Kondo, Zyunko Morihara, Yuka Ikeda, Hideyuki Sumida, Youko Ninomiya, Satoe Uesugi, Kimie Okazaki, Daisuke Yoshioka, Miyoko Kobayashi, Hideho Wada
{"title":"Efficacy of baloxavir marboxil as a prophylactic against influenza among in-patients and analysis of influenza virus mutations in their isolates at a Japanese hospital during the 2023-2024 flu season.","authors":"Akihide Fujii, Tomohiro Oishi, Eisei Kondo, Zyunko Morihara, Yuka Ikeda, Hideyuki Sumida, Youko Ninomiya, Satoe Uesugi, Kimie Okazaki, Daisuke Yoshioka, Miyoko Kobayashi, Hideho Wada","doi":"10.1186/s40780-025-00418-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Baloxavir marboxil (baloxavir) is a new anti-influenza drug that works as a cap-dependent endonuclease inhibitor. It is approved for prophylactic use against influenza in Japan, but there are few reports on this usage in hospitalized in-patients. It reportedly reduces patient susceptibility to influenza through a mechanism involving amino acid substitution.</p><p><strong>Methods: </strong>Between August 2023 and July 2024, we investigated the efficacy of baloxavir as a prophylactic against influenza among in-patients at our hospital who had close contact with patients who were infected with influenza viruses in the same rooms. We also investigated the I38T influenza virus variant to baloxavir through samples taken from patients with the virus at the hospital.</p><p><strong>Results: </strong>We enrolled a total of 45 in-patients who had close contact with other patients who were confirmed to be infected with influenza in the same room. Among 34 of them who were prescribed baloxavir prophylactically, none developed influenza within 5 days from their last contact with infected patients. Conversely, among the other 11 who did not use baloxavir, three became infected with influenza within 5 days following contact with the infected patient (P = 0.012). In 85 samples taken from the patients with influenza, 25 were H1N1 types and 60 were H3N2. We detected the I38T variant of the cap-dependent endonuclease-baloxavir complex structure in two of the H3N2-type samples. Both of these patients had contracted influenza from their children.</p><p><strong>Conclusions: </strong>According to our results, Baloxavir represents an effective prophylactic against influenza for hospitalized in-patients. However, patients with genetic mutations related to decreased susceptibility to influenza, such as I38T variant, should nevertheless exercise higher levels of caution-particularly around children.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"11 1","pages":"22"},"PeriodicalIF":1.2000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912740/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Health Care and Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40780-025-00418-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Baloxavir marboxil (baloxavir) is a new anti-influenza drug that works as a cap-dependent endonuclease inhibitor. It is approved for prophylactic use against influenza in Japan, but there are few reports on this usage in hospitalized in-patients. It reportedly reduces patient susceptibility to influenza through a mechanism involving amino acid substitution.

Methods: Between August 2023 and July 2024, we investigated the efficacy of baloxavir as a prophylactic against influenza among in-patients at our hospital who had close contact with patients who were infected with influenza viruses in the same rooms. We also investigated the I38T influenza virus variant to baloxavir through samples taken from patients with the virus at the hospital.

Results: We enrolled a total of 45 in-patients who had close contact with other patients who were confirmed to be infected with influenza in the same room. Among 34 of them who were prescribed baloxavir prophylactically, none developed influenza within 5 days from their last contact with infected patients. Conversely, among the other 11 who did not use baloxavir, three became infected with influenza within 5 days following contact with the infected patient (P = 0.012). In 85 samples taken from the patients with influenza, 25 were H1N1 types and 60 were H3N2. We detected the I38T variant of the cap-dependent endonuclease-baloxavir complex structure in two of the H3N2-type samples. Both of these patients had contracted influenza from their children.

Conclusions: According to our results, Baloxavir represents an effective prophylactic against influenza for hospitalized in-patients. However, patients with genetic mutations related to decreased susceptibility to influenza, such as I38T variant, should nevertheless exercise higher levels of caution-particularly around children.

2023-2024年流感季节日本某医院住院患者预防流感的效果及分离株流感病毒突变分析
背景:巴洛昔韦(Baloxavir marboxil, Baloxavir)是一种新型抗流感药物,是一种帽依赖性核酸内切酶抑制剂。在日本,它被批准用于预防流感,但很少有关于住院病人使用它的报道。据报道,它通过一种涉及氨基酸替代的机制降低了患者对流感的易感性。方法:在2023年8月至2024年7月期间,对与同一病房感染流感病毒的患者有密切接触的住院患者进行巴洛韦预防流感的疗效调查。我们还通过从医院感染该病毒的患者身上采集的样本调查了巴洛韦的I38T流感病毒变体。结果:我们共招募了45名与同一房间的其他确诊流感患者有密切接触的住院患者。在预防性服用巴洛韦的34名患者中,没有人在最后一次接触受感染患者后5天内患上流感。相反,在未使用巴洛韦的11人中,有3人在与感染患者接触后5天内感染流感(P = 0.012)。从流感患者身上采集的85份样本中,25份为H1N1型,60份为H3N2型。我们在两个h3n2型样本中检测到帽依赖性内切酶-巴洛昔韦复合物结构的I38T变体。这两名病人都是从他们的孩子那里感染流感的。结论:根据我们的研究结果,巴洛昔韦对住院患者是一种有效的流感预防药物。然而,患有与流感易感性降低相关的基因突变(如I38T变异)的患者仍应提高警惕,特别是在儿童周围。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.80
自引率
0.00%
发文量
29
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信